We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · June 24, 2022

Effect of Dapagliflozin on Kidney and Cardiovascular Outcomes by Baseline KDIGO Risk Categories

Diabetologia

 

Additional Info

Diabetologia
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
Diabetologia 2022 Jul 01;65(7)1085-1097, SW Waijer, P Vart, DZI Cherney, GM Chertow, N Jongs, AM Langkilde, JFE Mann, O Mosenzon, JJV McMurray, P Rossing, R Correa-Rotter, BV Stefansson, RD Toto, DC Wheeler, HJL Heerspink

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading